Glenmark Pharmaceuticals on Thursday said it has launched a novel fixed-dose combination (FDC) drug in the country for patients with uncontrolled asthma.

The Mumbai-based drug major has launched – Indacaterol + Mometasone FDC under the brand name Indamet.

The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg and 320 mcg to be taken once daily.


is a key focus area for Glenmark, and the company leads from the front in providing access to the latest treatment options to patients.

“We are proud to introduce this novel fixed-dose combination Indamet, which is the first of its kind in India, offering an affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma,” Glenmark Pharmaceuticals Group Vice President & Head (India Formulations) Alok Malik said in a statement.
No Comments For This Post, Be first to write a Comment.
Leave a Comment
Enter the code shown:

Can't read the image? click here to refresh

Todays Epaper

neerus indian ethnic wear
Latest Urdu News

Do you think Rishi Sunak can win the race to be the next UK prime minister?

Can't Say
aaddaily.com-Banner4 -->